Viridian Therapeutics (VRDN)

• Market cap: $2.74B
• 1 day: 0.98%
• 5 days: 3.6%
• 1 month: 38.45%
• 3 months: 56.02%
• 6 months: 132.39%
• Year to date: 45.6%
• 1 year: 32.95%
• 5 years: 82.55%
• 10 years: -83.18%
• Sector: Healthcare
• Industry: Biotechnology

About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Employees: 143